Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma

被引：0

作者：

Patrick B. Johnston

Lauren C. Pinter-Brown

Ghulam Warsi

Kristen White

Radhakrishnan Ramchandren

机构：

[1] Mayo Clinic,Division of Hematology

[2] David Geffen School of Medicine at UCLA,Department of Hematology/Oncology

[3] Novartis Pharmaceuticals Corporation,Department of Oncology

[4] Karmanos Cancer Institute,Department of Hematology/Oncology

来源：

Experimental Hematology & Oncology | / 7卷

关键词：

Clinical trial; Everolimus; Hodgkin lymphoma; mTOR inhibitors; Relapsed/refractory;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 145 条

[71]

MacLeod RAF(undefined)undefined undefined undefined undefined-undefined

[72]

De J(undefined)undefined undefined undefined undefined-undefined

[73]

Brown RE(undefined)undefined undefined undefined undefined-undefined

[74]

Yee KW(undefined)undefined undefined undefined undefined-undefined

[75]

Zeng Z(undefined)undefined undefined undefined undefined-undefined

[76]

Konopleva M(undefined)undefined undefined undefined undefined-undefined

[77]

Verstovsek S(undefined)undefined undefined undefined undefined-undefined

[78]

Ravandi F(undefined)undefined undefined undefined undefined-undefined

[79]

Ferrajoli A(undefined)undefined undefined undefined undefined-undefined

[80]

Ghobrial IM(undefined)undefined undefined undefined undefined-undefined